Author:
Hasserjian Robert P,Chen Steve,Perkins Sherrie L,de Leval Laurence,Kinney Marsha C,Barry Todd S,Said Jonathan,Lim Megan S,Finn William G,Medeiros L Jeffrey,Harris Nancy L,O'Malley Dennis P
Publisher
Springer Science and Business Media LLC
Subject
Pathology and Forensic Medicine
Reference26 articles.
1. Pucino Jr F, Harbus PT, Goldbach-Mansky R . Use of biologics in rheumatoid arthritis: where are we going? Am J Health Syst Pharm 2006;63:S19–S41.
2. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196–2204.
3. Van Lent PL, Van De Loo FA, Holthuysen AE, et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995;22:2250–2258.
4. Park SH, Kim CG, Kim JY, et al. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 2008;28:475–477.
5. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. J Dermatol 2006;213:204–214.